Pharmaceutical Manufacturing (FDA/DEA) — regulation & compliance changes
Drug manufacturers and API/contract producers tracking FDA cGMP and drug-approval actions, DEA controlled-substance rescheduling and quotas, and trade actions on pharmaceutical inputs — where a cGMP finding, rescheduling, or import ruling can halt a product line.
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock so you never have to refresh a government page again. Every detected change becomes a plain-English briefing covering what changed, who it affects, what you must do, and by when. Forewarned is forearmed.
Stay ahead of every Pharmaceutical Manufacturing (FDA/DEA) change
Real-time alerts, plain-English impact briefs, and a full searchable history — 100+ changes tracked in Pharmaceutical Manufacturing (FDA/DEA) so far.
Start your 7-day free trial✓ No card charged during your trial · ✓ Cancel anytime · ✓ Every alert links to the official source
Recent changes in Pharmaceutical Manufacturing (FDA/DEA)
- FDA Issues Final Rule Clarifying Evidence of Off-Lab... - Dechert
- Schedules of Controlled Substances: Temporary Placement of 5,6-Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I of the Controlled Substances Act
- International Drug Scheduling; Single Convention on Narcotic Drugs; Convention on Psychotropic Substances; Clobromazolam (Phenazolam); Cychlorphine (N-Propionitrile Chlorphine); Desalkylgidazepam (Bromonordiazepam); Ethylbromazolam; Etomethazene (5-Methyl Etodesnitazene); Spirochlorphine (R6980); Etomidate; Medetomidine; Request for Comments
- Determination That CABAZITAXEL (Cabazitaxel) Solution (Injection), 60 Milligrams/6 Milliliters (10 Milligrams/Milliliter), Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- PA HB 2749: An Act amending the act of April 14, 1972 (P.L.233, No.64), known as The Controlled Substance, Drug, Device and Cosmetic Act, further providing for drug overdose medication.
- Schedules of Controlled Substances: Placement of Cipepofol in Schedule IV
- US-CONGRESS BILLS-119hr10133ih: Fair Prescription Pricing Act of 2026
- Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I
- FDA declares Novo Nordisk plant, key to drug manufacturing for some biotechs, out of compliance - STAT
- Schering-Plough agrees to pay FDA $500 million and bring factories into compliance - American Veterinary Medical Association
- Florida Company Receives FDA Warning Letter - PharmTech.com
- New R.I. law protects patients who rely on specialty infusion drugs - Providence Business News
- FDA Suspends License of Gayatri Mewad in Chhatrapati Sambhajinagar Over Safety Lapses - LatestLY
- Commissioner's National Priority Voucher (CNPV) Pilot Program - fda.gov
- FDA warns firm for inappropriate use of AI in drug manufacturing - RAPS
- DEA Urges Judge to Move Marijuana to Schedule III as Final Rescheduling Briefs Set Stage for Decision - The Marijuana Herald
- 5,000 ppm fluoride toothpaste needs expert guidance, FDA says - Nation Thailand
- FDA issues draft guidance on assessing container and closure systems for drugs and biologics - RAPS
- FDA’s New Rules Aim to Make Pharma Ads Easier to Understand - Pain News Network
- Evaluation of Therapeutic Equivalence; Guidance for Industry; Availability
- Food and Drug Administration Modernization Act of 1997: Modifications to the List of Recognized Standards, Recognition List Number: 066
- Express Scripts, PCMA sue to block Tennessee law breaking up PBMs and pharmacies - Healthcare Dive
- 10 pharma execs charged with illegally selling 70M Opioid Pill - fda.gov
- Marijuana Rescheduling in Jeopardy? A Federal Court is About to Decide Whether the Attorney General Acted Improperly - newswire.com
- Lupin Receives EIR from U.S. FDA for its Somerset Manufacturing Facility - Lupin | Press Release - lupin.com
- Oklahoma legislature passes law intended to protect 340B drug program - The Journal Record
- Biosimilars substitution bill becomes law in South Dakota - Generics and Biosimilars Initiative
- FDA Allowing Florida to Import Cheaper Drugs from Canada - Supply Chain Brain
- Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability
- Novo Nordisk's US headquarters under fire in latest FDA warning letter - fiercepharma.com
- U.S. FDA Proposes Updated Registration Framework for Distributed Drug Manufacturing - arcweb.com
- Guidance: Potency Assessment of Active Immunotherapy Products
- FDA’s rule seeks to modernize drug manufacturing registration - PharmaLive
- FDA draft guidance operationalizes animal testing phaseout - Hogan Lovells Cadwalader
- FDA plans rules to rein in drug ads, enable proactive release of CRLs, and more - raps.org
- United States District Court Upholds Vermont Statute Prohibiting Use of Prescriber-Identifiable Prescription Information for Marketing Purposes - mcguirewoods.com
- FDA proposes drug registration changes to boost supply chain transparency - aha.org
- Guidance: Determining Whether to Submit an ANDA or a 505(b)(2) Application
- FDA drafts guidance on using next-generation sequencing to assess gene therapy safety - raps.org
- FDA proposes rule to ease registration for distributed manufacturers, require foreign API sites to register - raps.org
- FDA proposes rule to streamline drug manufacturing registration By Investing.com - Investing.com Canada
- Not Joking Around: FDA Offers Additional Clarification on Compounded GLP-1 Policy in April Fool’s Day Announcement - natlawreview.com
- Congress Introduces SAFE Drugs Act of 2025, Expanding FDA Oversight of Compounded GLP-1 Drugs and Telehealth Providers - dykema.com
- TX SB 18: Relating to prohibitions on the manufacture and provision of abortion-inducing drugs, including the jurisdiction of and effect of certain judgments by courts within and outside this state with respect to the manufacture and provision of those drugs, and to protections from certain counteractions under the laws of other states and jurisdictions; authorizing qui tam actions.
- FDA Proposes New Registration and Listing Pathway for Distributed Manufacturing and Aligns Foreign Establishment Obligations With Current Law - arnoldporter.com
- FDA issues first cGMP warning letter citing AI misuse in pharmaceutical manufacturing - manufacturingchemist.com
- FDA makes groundbreaking decision to waive clinical efficiency studies for monoclonal antibody biosimilars - Manufacturing Chemist
- FDA Clarifies Policies for Pharmacy Compounders of GLP-1 Products - foley.com
- US FDA proposes rule to simplify registration for some drug manufacturers - reuters.com
- Alito temporarily restores FDA rule allowing abortion pill mifepristone to be sent by mail - cbsnews.com
- Determination That ANSAID (Flurbiprofen) Tablets, 50 Milligrams and 100 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- US-CONGRESS BILLS-119hr10094ih: Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2026
- Ohio House passes bill to legalize and tax ‘intoxicating hemp;’ prohibit marijuana use in public places - signalohio.org
- FDA bans Red 3 dye from food and drugs – a scientist explains the artificial color’s health risks and long history - The Conversation
- Withdrawal of Approval of Drug Application: Kremers Urban Pharmaceuticals, Inc., Extended-Release Methylphenidate Tablets; Grant of Hearing Request
- Supreme Court preserves telehealth access to abortion pill mifepristone pending appeal - Jurist.org
- Fifth Circuit Stay Reinstates Nationwide In-Person Dispensing Requirement for Mifepristone - Reed Smith LLP
- Schedules of Controlled Substances: Rescheduling of Suvorexant, Lemborexant, and Daridorexant from Schedule IV into Schedule V
- FDA moves to expose hidden foreign drug factories, strengthen domestic production in sweeping rule proposal - foxbusiness.com
- The FDA let substandard factories ship these medications to the U.S. - michiganadvance.com
- Tom’s of Maine says it will remedy mold, bacteria problems found by FDA at Sanford plant - mainebiz.biz
- The FTC Challenges Companies’ Allegedly Improper Orange Book Patent Listings - skadden.com
- Alabama Board of Medical Examiners Issues Warning of Non-FDA-Approved Peptides - drugtopics.com
- Psychedelics Policy Newsletter: DEA considers rescheduling psilocybin, FDA releases rejection decision, and more - reason.org
- Novo plant hit with FDA's most serious inspection classification, portending possible delays for partners - fiercepharma.com
- FDA expectations create potential friction in new Form 483 response guidance - fiercepharma.com
- Lupin's Novel Laboratories knocked by FDA for cleanliness, quality issues at New Jersey plant - fiercepharma.com
- August 4, 2025: Pennsylvania pharmacy owner indicted and 14 licenses revoked in Ohio - Partnership for Safe Medicines
- Legal Updates on Arkansas Law Banning PBMs From Owning Affiliated Pharmacies - bipc.com
- WV can restrict abortion pill access, appeals court says - westvirginiawatch.com
- DiscGenics Announces US FDA Approval to Proceed with Phase III Clinical Evaluation - techbuzznews.com
- May 11, 2026: Connecticut AG’s crackdown leads to major platform halting sales of “research grade” weight loss chemicals to U.S. - safemedicines.org
- Senate Unanimously Passes Boscola-Backed Legislation to Modernize Pharmaceutical Licensing - pasenate.com
- USFDA flags 3 manufacturing compliance lapses at Lupin's New Jersey unit - Business Standard
- Comments on DEA’s proposed rule on manufacturing and procurement quotas - brookings.edu
- Arkansas passes law banning PBMs from owning pharmacies - Healthcare Dive
- State Marijuana Products Can Not Enter Schedule III Without Demonstrating the Chemical Consistency Required by Federal Regulation - newswire.com
- MMJ International Holdings Joins Legal Challenge to Trump's Cannabis Rescheduling Order - newswire.com
- Federal Judge to Decide Whether Medicare Can Distribute Hemp-Marijuana Cannabinoids Without FDA Approval - newswire.com
- MMJ International Holdings Advances D.C. Circuit Challenge to DEA Marijuana Rescheduling Order - newswire.com
- Marijuana Rescheduling Countdown: Why the "Order of Operations" and Todd Blanche's Appointment Define the Path to Schedule III - newswire.com
- Marijuana Rescheduling or Regulatory Failure? D.C. Appellate Court Will Rule - newswire.com
- Ten Pharmaceutical Distributor Executives, Sales Representatives, and Brokers Charged in Connection with Unlawful Sales of Nearly 70M Opioid Pills - justice.gov
- Mississippi Establishes New Medical Device Establishment License and Expands Definition of “Device” - JD Supra
- MMJ International Holdings Files Formal Challenge To DEA Marijuana Rescheduling As Constitutional, Treaty, And Pharmaceutical Questions Collide - newswire.com
- Congress Orders DEA Crackdown on Intoxicating Cannabinoids While CMS Continues Expanding Medicare CBD Access - newswire.com
- DEA's New Marijuana Registration Questions Redefining the Cannabis Industry - And MMJ International Already Has the Answer - newswire.com
- New Yorkers could be popping cheaper Canadian prescription drugs if proposed bill succeeds - nysenate.gov
- FDA allows Colorado drug imports, in theory - politico.com
- 3 States Challenge Trump DOJ’s Schedule III Cannabis Rule - cannabisbusinesstimes.com
- FDA Proposes Rule to Modernize Drug Manufacturing Registration - wboc.com
- Novo gets FDA warning letter at troubled Indiana site formerly owned by Catalent - Fierce Pharma
- Psychedelic drugs get the FDA fast-track - politico.com
- Louisiana Attorney General challenges FDA rule allowing abortion pills by mail - The Town Talk
- FDA rolls out new rare-disease drug playbook - politico.com
- Appeals court approves sweeping abortion pill restrictions, teeing up SCOTUS showdown - politico.com
- Novo Nordisk’s Indiana Plant Flagged by FDA for Contamination and Safety Lapses - pharmaceuticalcommerce.com
- Local biotech to expand stem cell production as Florida law opens new market - bizjournals.com
- King Pharmaceuticals Fined For Air Pollution - cen.acs.org
- Advocates win a lawsuit to remove cannabis from the Schedule 1 drug list - thenevadaindependent.com
Frequently asked questions
What does Aforeworn monitor for Pharmaceutical Manufacturing (FDA/DEA)?
Aforeworn continuously tracks the official rules, ordinances, fee schedules and licensing requirements that affect Pharmaceutical Manufacturing (FDA/DEA), detects every change, and explains in plain English what changed, who it hits and what to do.
How fast will I hear about a change in Pharmaceutical Manufacturing (FDA/DEA)?
Changes are detected automatically as sources update, and subscribers are alerted in real time — often before the change is widely reported.
Why does staying current on Pharmaceutical Manufacturing (FDA/DEA) matter?
A single missed change can mean fines, a lapsed licence, or lost eligibility. Forewarned is forearmed — knowing first lets you act before it costs you.